Ascendia Pharmaceuticals offers a comprehensive suite of pre-formulation for preclinical- and clinical-stage drug candidates.
Ascendia Pharmaceuticals has raised $2.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2025.
Ascendia Pharmaceuticals's investors include Signet Healthcare Partners.
Ascendia Pharmaceuticals is headquartered in North Brunswick, United States.
Ascendia Pharmaceuticals offers a comprehensive suite of pre-formulation for preclinical- and clinical-stage drug candidates.
Ascendia Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ascendia Pharmaceuticals — Funding & Investors." VCBacked, June 4, 2025, https://www.vcbacked.co/company/ascendia-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2025). Ascendia Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ascendia-pharmaceuticals
{{cite web |title=Ascendia Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/ascendia-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated